Latest Period
Q2 2026
Security Snapshot
Arcus Biosciences, Inc. - Common Stock, par value $0.0001 (RCUS) Institutional Ownership
CUSIP: 03969F109
13F Institutional Holders and Ownership History from Q1 2018 to Q2 2026
Institutions Reporting
227
Shares (Excl. Options)
122,460,121
Price
$30.83
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001
- Symbol
- RCUS on NYSE
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 122,460,121
- Total 13F value
- $3,774,434,971
- Portfolio coverage rank
- 0%
- Share change
- +3,717,569
- Value change
- +$135,134,215
- Number of holders
- 227
- Shares outstanding
- 127,225,749
- SEC-reported price per share
- $27.05
- Insider filing price
- $27.05
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RCUS - Arcus Biosciences, Inc. - Common Stock, par value $0.0001 is tracked under CUSIP 03969F109.
- 227 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 208 to 227 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $2,572,356,108 to $3,774,434,971.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 227 institutions filings for Q2 2026.
Security key
03969F109
Latest holder period
Q2 2026
13F holders
227
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
RCUS full holder history
Arcus Biosciences, Inc. SEC filings
Arcus Biosciences, Inc. company facts
Arcus Biosciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03969F109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
RCUS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 25% | -3.5% | $882,093,013 | 31,424,760 | 0% | Gilead Sciences, Inc. | 05 Aug 2026 | |
| BlackRock, Inc. | 10% | +11% | $303,514,602 | +$65,766,227 | 12,736,927 | +28% | BlackRock, Inc. | 31 Dec 2025 |
| Point72 Asset Management, L.P. | 4.1% | -28% | $58,921,714 | -$20,381,232 | 4,332,479 | -26% | Point72 Asset Management, L.P. | 30 Sep 2025 |
As of 30 Jun 2026, 227 institutional investors reported holding 122,460,121 shares of Arcus Biosciences, Inc. - Common Stock, par value $0.0001 (RCUS). This represents 96% of the company’s total 127,225,749 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
82%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 25% | 31,424,760 | 0% | 59% | $968,825,351 |
| BlackRock, Inc. | 13% | 16,416,249 | +7.8% | 0.01% | $506,112,958 |
| STATE STREET CORP | 4.7% | 6,029,484 | +11% | 0.01% | $185,888,992 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.6% | 5,895,448 | -3.2% | 0.03% | $181,756,661 |
| MONTANOVA CAPITAL, LLC | 3.8% | 4,776,423 | -5.1% | 3.1% | $147,257,121 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.5% | 4,475,528 | +4.8% | 0.01% | $137,980,528 |
| FMR LLC | 3.2% | 4,049,757 | +248% | 0.01% | $124,854,021 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.1% | 3,888,346 | +0.82% | 0% | $119,877,707 |
| CITADEL ADVISORS LLC | 2.5% | 3,135,057 | +136% | 0.06% | $96,653,807 |
| Woodline Partners LP | 2.4% | 3,007,798 | -20% | 0.29% | $92,730,412 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 2,448,749 | +8.7% | 0% | $75,507,790 |
| Siren, L.L.C. | 1.9% | 2,420,430 | -20% | 1.5% | $74,621,857 |
| Fisher Asset Management, LLC | 1.7% | 2,139,396 | -2.3% | 0.02% | $65,957,578 |
| MARSHALL WACE, LLP | 1.5% | 1,945,088 | -48% | 0.05% | $59,967,064 |
| SAMLYN CAPITAL, LLC | 1.2% | 1,547,182 | -19% | 0.79% | $47,699,621 |
| DIMENSIONAL FUND ADVISORS LP | 1.1% | 1,434,320 | +0.57% | 0.01% | $44,221,943 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.1% | 1,419,533 | -14% | 0.04% | $43,764,202 |
| GOLDMAN SACHS GROUP INC | 1.1% | 1,387,566 | +39% | 0% | $42,778,660 |
| Soleus Capital Management, L.P. | 0.92% | 1,168,738 | +159% | 1.2% | $36,032,193 |
| Sofinnova Investments, Inc. | 0.74% | 945,690 | +2.4% | 1.6% | $29,155,623 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.74% | 941,756 | +4.2% | 0% | $29,034,337 |
| NORTHERN TRUST CORP | 0.73% | 932,523 | +11% | 0% | $28,749,685 |
| Parkman Healthcare Partners LLC | 0.72% | 919,266 | -24% | 2.9% | $28,340,971 |
| Invesco Ltd. | 0.66% | 845,233 | +3% | 0% | $26,058,533 |
| BAKER BROS. ADVISORS LP | 0.66% | 844,816 | +103% | 0.13% | $26,045,677 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
34
Latest
Q2 2026
Rows shown
1-25 of 34
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 122,460,121 | $3,774,434,971 | +$135,134,215 | $30.83 | 227 |
| 2026 Q1 | 119,078,221 | $2,572,356,108 | -$79,675,032 | $21.60 | 208 |
| 2025 Q4 | 121,424,353 | $2,893,305,835 | +$498,497,157 | $23.83 | 208 |
| 2025 Q3 | 100,610,243 | $1,368,169,306 | +$17,470,409 | $13.60 | 186 |
| 2025 Q2 | 99,735,332 | $811,386,525 | +$23,005,595 | $8.14 | 181 |
| 2025 Q1 | 97,195,653 | $762,981,433 | +$76,941,552 | $7.85 | 183 |
| 2024 Q4 | 83,908,968 | $1,249,338,646 | -$21,214,675 | $14.89 | 185 |
| 2024 Q3 | 53,324,923 | $815,463,718 | +$21,618,657 | $15.29 | 184 |
| 2024 Q2 | 51,955,193 | $791,285,512 | -$15,709,425 | $15.23 | 191 |
| 2024 Q1 | 52,828,671 | $997,275,069 | +$741,376 | $18.88 | 169 |
| 2023 Q4 | 52,818,611 | $1,008,878,346 | -$1,266,933 | $19.10 | 181 |
| 2023 Q3 | 52,811,112 | $947,947,087 | -$30,726,648 | $17.95 | 184 |
| 2023 Q2 | 54,702,646 | $1,110,123,478 | -$11,409,103 | $20.31 | 177 |
| 2023 Q1 | 55,490,875 | $1,012,137,432 | +$17,396,401 | $18.24 | 177 |
| 2022 Q4 | 53,808,832 | $1,112,728,096 | +$17,661,819 | $20.68 | 199 |
| 2022 Q3 | 52,505,739 | $1,373,608,654 | -$54,087 | $26.16 | 171 |
| 2022 Q2 | 52,444,913 | $1,329,092,467 | -$15,970,235 | $25.34 | 162 |
| 2022 Q1 | 50,609,470 | $1,598,261,880 | -$43,817,366 | $31.56 | 146 |
| 2021 Q4 | 50,826,972 | $2,056,609,533 | +$107,109,155 | $40.47 | 136 |
| 2021 Q3 | 48,251,727 | $1,682,950,642 | +$59,932,851 | $34.87 | 127 |
| 2021 Q2 | 45,147,112 | $1,239,729,813 | +$11,589,356 | $27.46 | 125 |
| 2021 Q1 | 44,736,322 | $1,254,917,338 | +$7,899,154 | $28.08 | 143 |
| 2020 Q4 | 44,575,673 | $1,157,187,273 | +$10,417,742 | $25.96 | 143 |
| 2020 Q3 | 44,391,126 | $760,991,949 | +$17,571,170 | $17.14 | 127 |
| 2020 Q2 | 41,840,912 | $1,034,233,021 | +$380,488,277 | $24.74 | 138 |